Roivant Sciences Ltd. (roiv)
ROIV — Company Overview
Roivant Sciences Ltd. (ROIV) trades on NMS as part of the Healthcare peer group (Biotechnology).
| Ticker | ROIV |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NMS |
| Market cap | $26.60B |
| Last price | $36.82 |
| Size category | Large Cap |
ROIV — Business Description
ROIV represents a Biotechnology business in the Healthcare segment. Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a…
Official website: https://roivant.com.
ROIV — Investment Thesis
At a high level, ROIV offers exposure to Healthcare with metrics outlined below from public market data.
- Revenue is contracting at roughly -33.5% year-over-year (public data).
- Equity market capitalization is approximately $26.60B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
ROIV — Financial Health
Key financial health indicators for Roivant Sciences Ltd. are derived exclusively from public data — no proprietary estimates.
Profit margin near 0.0% leaves a narrower cushion versus higher-margin peers. Negative free cash flow of $-1.13B may require careful capital allocation.
| Forward P/E | -21.44× |
| Price / Sales | 3531.06× |
| Price / Book | 6.29× |
| Gross margin | 0.0% |
| Operating margin | -254.1% |
| Profit margin | 0.0% |
| Return on equity | -8.5% |
| Debt / Equity | 2.18 |
| Free cash flow | $-1.13B |
ROIV — Growth Outlook
Growth outlook for Roivant Sciences Ltd. (ROIV) depends on demand trends in Biotechnology and the company's ability to convert revenue into sustainable earnings.
- Revenue decline of -33.5% highlights near-term demand headwinds.
- Price is 13.4% below the 52-week high.
ROIV — Competitive Position
Roivant Sciences Ltd. (ROIV) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Biotechnology.
- Market capitalization of $26.60B places ROIV among large-cap peers.
- Gross margin of 0.0% should be benchmarked against direct competitors.
ROIV — Strengths
Strengths for Roivant Sciences Ltd. (ROIV) inferred from public financial metrics:
- Moderate leverage (debt/equity 2.18).
- Large Cap scale ($26.60B) may provide distribution and funding advantages.
ROIV — Weaknesses
Weaknesses and pressure points for Roivant Sciences Ltd. (ROIV) based on available data:
- Revenue contraction of -33.5% year-over-year.
- Thin profit margin (0.0%).
- Negative free cash flow ($-1.13B).
ROIV — Opportunities
- Opportunities depend on industry trends and execution — monitor quarterly filings and guidance.
ROIV — Risks
- Negative revenue growth may signal share loss or cyclical pressure.
- Thin margins leave less room for operational missteps.
ROIV — Summary
Roivant Sciences Ltd. (ROIV) is a large-cap Healthcare company focused on Biotechnology, listed on NMS. Last price $36.82 with market cap $26.60B. Revenue declined -33.5% year-over-year per public data. Notable strengths include moderate leverage (debt/equity 2.18). Key watch items include revenue contraction of -33.5% year-over-year. Premium Terminal tools for Roivant Sciences Ltd. add ownership analytics, news, and richer estimate history beyond this public summary.
Start Free — open ROIV in Vest Terminal
Access live data, filings, ownership, and analysis for Roivant Sciences Ltd..
Roivant Sciences Ltd. FAQ
What does Roivant Sciences Ltd. (ROIV) do?
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development acros…
What is ROIV's P/E ratio?
Roivant Sciences Ltd. has a trailing P/E of N/A× based on publicly available market data.
Does ROIV pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is ROIV in?
Roivant Sciences Ltd. is classified in Healthcare (Biotechnology) on NMS.
What is ROIV's market capitalization?
Approximate market cap: $26.60B.
What are the main risks for ROIV?
Key risks include negative revenue growth, among factors on this page.
What are the strengths of ROIV?
Potential positives include moderate leverage (debt/equity 2.18), large cap scale ($26.60b) may provide distribution and funding advantages.
Where can I get analyst estimates for ROIV?
Public analyst price targets and consensus for Roivant Sciences Ltd. are on the free /stocks/roiv/estimates page. Deeper estimate history and models are available in Vest Terminal.